actually no kbear1, in the interests of keeping this thread factual I will spell my point out more clearly for you:
of the 36 CVac patients, we will not have 1 year data for most of them. if you remember correctly, it was only in 2011 that the company announced the first 7 patients have been safely administered, that they can now start recruiting the remaining patients. hence in october 2012 the final patient receives final dose of CVac, and in early october we get ICS data for just 6 patients, as well as interim safety data.
if someone wants to talk about efficacy after this measly data point, they are delusional. those that are betting on a fast-tracked approval in 2013/14 based off 37 patient data, are even more delusional. but hey there are a lot of misguided people in this stock (as the share price chart tells you).
PRR Price at posting:
9.8¢ Sentiment: LT Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)